News

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

What are the current, emerging mental health concerns?

Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.

Here are highlights from this week in Psychiatric Times, including conference updates and trial news.

Let's reflect on managed care as we celebrate the 40th anniversary of Psychiatric Times.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Today, let’s be loving to the environment and each other.

A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.

Check out these 7 insights and perspectives on recognizing and treating PTSD.

Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

"It is the winter of chest pain and snow, all the drunks smashed through the ER doors..."

Is physician burnout slowing down?

Stephen Mateka, DO, Psychiatric Times' new Child & Adolescent Psychiatry Section Editor, shares thoughts and insights.

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.

Test-drive this 7-fold model in your own practice.

The therapeutic nature of crying, in all professions…

MindMed has announced the dosing of the first patient in its second Phase 3 study of MM120.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

A clinician’s search for flexibility, autonomy, and ethical care leads her to a private practice that redefines work-life balance in medicine.

Did you watch the Super Bowl?

Here are highlights from this week in Psychiatric Times, including trial updates and a new approach to treating a surprising condition.

While health care is no game, we certainly are all a team, striving together toward 1 united goal: improving patient care and outcomes.

The current controversy: whether individuals who have transitioned physically and hormonally from a male gender identity to a female gender identity have an undue and significant advantage in sports.

Check out these bite-sized reviews of books related to mental health.

New Hampshire’s mental health system faces ongoing challenges with emergency department boarding, legal concerns over due process, and resource shortages, prompting reforms to improve patient care and access.

Learn more about the latest research on the impact the endocrine system has on major depressive disorder.